mRNA-1273 Has High Vaccine Effectiveness After Five Months
The vaccine effectiveness of two doses of Moderna mRNA-1273 is 87.4% against COVID-19 infection and 95.8 and 97.9% against COVID-19 hospitalization and hospital death, respectively.
The vaccine effectiveness of two doses of Moderna mRNA-1273 is 87.4% against COVID-19 infection and 95.8 and 97.9% against COVID-19 hospitalization and hospital death, respectively.
Most cases of suspected COVID-19 vaccine-related myocarditis occurring in young people have a mild clinical course.
Most vaccinated American adults have every intention of getting booster shots.
BNT162b2 elicits relatively lower antibody levels to the SARS-CoV-2 spike receptor binding domain than mRNA-1273, and lower antibody levels are observed with BNT162b2 in older versus younger adults.
In 2020, there were increases in the incidence of health care-associated infection.
The 24-week risk for COVID-19 outcomes is slightly lower after vaccination with mRNA-1273 than BNT162b2.
U.S. government worker compliance with the COVID-19 vaccination mandate had reached 95 percent as of Monday.
Both Companies provided data demonstrating waning neutralizing antibody titers approximately 6 months after completion of the primary series.
For patients with severe mental illness, a smartphone intervention is highly usable and acceptable and improves outcomes.
– A considerable proportion of hospital-based health care personnel (HCP) remain unvaccinated against COVID-19.